Literature DB >> 23876235

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Brigid C Browne1, Falko Hochgräfe, Jianmin Wu, Ewan K A Millar, Jane Barraclough, Andrew Stone, Rachael A McCloy, Christine S Lee, Caroline Roberts, Naveid A Ali, Alice Boulghourjian, Fabian Schmich, Rune Linding, Lynn Farrow, Julia M W Gee, Robert I Nicholson, Sandra A O'Toole, Robert L Sutherland, Elizabeth A Musgrove, Alison J Butt, Roger J Daly.   

Abstract

Acquired resistance to the anti-estrogen tamoxifen remains a significant challenge in breast cancer management. In this study, we used an integrative approach to characterize global protein expression and tyrosine phosphorylation events in tamoxifen-resistant MCF7 breast cancer cells (TamR) compared with parental controls. Quantitative mass spectrometry and computational approaches were combined to identify perturbed signalling networks, and candidate regulatory proteins were functionally interrogated by siRNA-mediated knockdown. Network analysis revealed that cellular metabolism was perturbed in TamR cells, together with pathways enriched for proteins associated with growth factor, cell-cell and cell matrix-initiated signalling. Consistent with known roles for Ras/MAPK and PI3-kinase signalling in tamoxifen resistance, tyrosine-phosphorylated MAPK1, SHC1 and PIK3R2 were elevated in TamR cells. Phosphorylation of the tyrosine kinase Yes and expression of the actin-binding protein myristoylated alanine-rich C-kinase substrate (MARCKS) were increased two- and eightfold in TamR cells respectively, and these proteins were selected for further analysis. Knockdown of either protein in TamR cells had no effect on anti-estrogen sensitivity, but significantly decreased cell motility. MARCKS expression was significantly higher in breast cancer cell lines than normal mammary epithelial cells and in ER-negative versus ER-positive breast cancer cell lines. In primary breast cancers, cytoplasmic MARCKS staining was significantly higher in basal-like and HER2 cancers than in luminal cancers, and was independently predictive of poor survival in multivariate analyses of the whole cohort (P < 0.0001) and in ER-positive patients (P = 0.0005). These findings provide network-level insights into the molecular alterations associated with the tamoxifen-resistant phenotype, and identify MARCKS as a potential biomarker of therapeutic responsiveness that may assist in stratification of patients for optimal therapy.
© 2013 FEBS.

Entities:  

Keywords:  MARCKS; MCF7; Yes kinase; endocrine resistance; phosphoproteomics

Mesh:

Substances:

Year:  2013        PMID: 23876235     DOI: 10.1111/febs.12441

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  21 in total

1.  Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.

Authors:  Robert T Dauchy; Shulin Xiang; Lulu Mao; Samantha Brimer; Melissa A Wren; Lin Yuan; Muralidharan Anbalagan; Adam Hauch; Tripp Frasch; Brian G Rowan; David E Blask; Steven M Hill
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

2.  Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.

Authors:  Zaynab Mousavian; Abbas Nowzari-Dalini; Ronald W Stam; Yasir Rahmatallah; Ali Masoudi-Nejad
Journal:  Cell Oncol (Dordr)       Date:  2016-10-31       Impact factor: 6.730

3.  Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

Authors:  C-H Chen; L W R Fong; E Yu; R Wu; J F Trott; R H Weiss
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

4.  Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab.

Authors:  Basma M Sharaf; Alexander D Giddey; Hamza M Al-Hroub; Varsha Menon; Javan Okendo; Raafat El-Awady; Muath Mousa; Ahmed Almehdi; Mohammad H Semreen; Nelson C Soares
Journal:  Cancer Chemother Pharmacol       Date:  2022-10-20       Impact factor: 3.288

5.  Targeting the phosphorylation site of myristoylated alanine-rich C kinase substrate alleviates symptoms in a murine model of steroid-resistant asthma.

Authors:  Chien-Neng Wang; Yu-Chao Lin; Bo-Chun Chang; Ching-Hsien Chen; Reen Wu; Chen-Chen Lee
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

6.  The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells.

Authors:  Yini Yang; Lavanya Choppavarapu; Kun Fang; Alireza S Naeini; Bakhtiyor Nosirov; Jingwei Li; Ke Yang; Zhijing He; Yufan Zhou; Rachel Schiff; Rong Li; Yanfen Hu; Junbai Wang; Victor X Jin
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-09-19       Impact factor: 4.490

7.  Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.

Authors:  Xinyan Wu; Muhammad Saddiq Zahari; Santosh Renuse; Raja Sekhar Nirujogi; Min-Sik Kim; Srikanth S Manda; Vered Stearns; Edward Gabrielson; Saraswati Sukumar; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2015-09-01       Impact factor: 5.911

8.  Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment.

Authors:  Ching-Hsien Chen; Chun-Ting Cheng; Yuan Yuan; Jing Zhai; Muhammad Arif; Lon Wolf R Fong; Reen Wu; David K Ann
Journal:  Oncotarget       Date:  2015-06-20

9.  MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.

Authors:  Dan Yu; George Makkar; Tuo Dong; Dudley K Strickland; Rajabrata Sarkar; Thomas Stacey Monahan
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

10.  Co-expression Network Analysis Reveals Key Genes Related to Ankylosing spondylitis Arthritis Disease: Computational and Experimental Validation.

Authors:  Leila Najafzadeh; Mahdi Mahmoudi; Mostafa Ebadi; Marzieh Dehghan Shasaltaneh
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.